Top-Rated StocksTop-RatedNASDAQ:CRNX Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Free CRNX Stock Alerts $46.50 -0.70 (-1.48%) (As of 04:28 PM ET) Add Compare Share Share Today's Range$46.20▼$48.1150-Day Range$37.93▼$48.0352-Week Range$15.76▼$49.58Volume561,205 shsAverage Volume762,364 shsMarket Capitalization$3.66 billionP/E RatioN/ADividend YieldN/APrice Target$54.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Crinetics Pharmaceuticals alerts: Email Address Crinetics Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.91 Rating ScoreUpside/Downside16.1% Upside$54.00 Price TargetShort InterestBearish6.63% of Shares Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.93Based on 4 Articles This WeekInsider TradingSelling Shares$8.51 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.34) to ($3.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.51 out of 5 starsMedical Sector262nd out of 908 stocksPharmaceutical Preparations Industry116th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingCrinetics Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCrinetics Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.63% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCrinetics Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Crinetics Pharmaceuticals has recently increased by 6.31%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCrinetics Pharmaceuticals does not currently pay a dividend.Dividend GrowthCrinetics Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCrinetics Pharmaceuticals has received a 46.37% net impact score from Upright. Crinetics Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Crinetics Pharmaceuticals is -0.62. Previous Next 2.2 News and Social Media Coverage News SentimentCrinetics Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Crinetics Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for CRNX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Crinetics Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,509,397.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Crinetics Pharmaceuticals is held by insiders.Percentage Held by Institutions98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.34) to ($3.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crinetics Pharmaceuticals is -12.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crinetics Pharmaceuticals is -12.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrinetics Pharmaceuticals has a P/B Ratio of 5.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlacePerma Bull: This is what terrifies me about AIFor 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.Go here now for this breaking story. About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More CRNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRNX Stock News HeadlinesApril 18, 2024 | insidertrades.comInsider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 14,375 Shares of StockApril 9, 2024 | insidertrades.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $2,013,560.67 in StockMay 6, 2024 | InvestorPlace (Ad)Perma Bull: This is what terrifies me about AIFor 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.May 2, 2024 | globenewswire.comCrinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024May 2, 2024 | americanbankingnews.comShort Interest in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Grows By 6.3%April 28, 2024 | americanbankingnews.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of "Moderate Buy" from BrokeragesApril 12, 2024 | finanznachrichten.deCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | finance.yahoo.comCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2024 | InvestorPlace (Ad)Perma Bull: This is what terrifies me about AIFor 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.April 11, 2024 | globenewswire.comCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | investing.comCrinetics Pharmaceuticals COO sells shares worth over $1.4 millionMarch 28, 2024 | insidermonkey.comInsiders Are Dumping These 5 Healthcare StocksMarch 27, 2024 | finance.yahoo.comInsider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)March 22, 2024 | finance.yahoo.comDirector Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)March 22, 2024 | finance.yahoo.comInsider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...March 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Crinetics Pharmaceuticals on Paltusotine’s Clinical Success and Market PotentialMarch 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Crinetics Pharmaceuticals Amid Impressive Paltusotine Trial ResultsMarch 21, 2024 | finance.yahoo.comCrinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 SharesMarch 19, 2024 | marketwatch.comCrinetics Pharmaceuticals Up on Positive Results for Acromegaly Drug TrialMarch 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Biogen (BIIB)March 19, 2024 | benzinga.comEndocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's WhyMarch 19, 2024 | finance.yahoo.comCrinetics Stock Jets 16% Higher, Reversing A Three-Week Decline On Its Phase 3 WinMarch 19, 2024 | reuters.comCrinetics Pharma's hormonal disorder drug meets main goal in late-stage studyMarch 19, 2024 | markets.businessinsider.comCrinetics Pharma Reports Positive Results From Phase 3 Studies Of Paltusotine For AcromegalyMarch 19, 2024 | msn.comCrinetics gains as late-stage trial for lead drug succeedsMarch 19, 2024 | finance.yahoo.comCrinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly PatientsMarch 19, 2024 | finance.yahoo.comUPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage studySee More Headlines Receive CRNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/06/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CRNX CUSIPN/A CIK1658247 Webwww.crinetics.com Phone(858) 450-6464FaxN/AEmployees290Year FoundedN/APrice Target and Rating Average Stock Price Target$54.00 High Stock Price Target$80.00 Low Stock Price Target$35.00 Potential Upside/Downside+15.8%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-214,530,000.00 Net Margins-4,223.27% Pretax Margin-5,216.32% Return on Equity-52.93% Return on Assets-45.54% Debt Debt-to-Equity RatioN/A Current Ratio13.07 Quick Ratio13.07 Sales & Book Value Annual Sales$4.01 million Price / Sales916.02 Cash FlowN/A Price / Cash FlowN/A Book Value$8.07 per share Price / Book5.78Miscellaneous Outstanding Shares78,740,000Free Float73,232,000Market Cap$3.67 billion OptionableOptionable Beta0.63 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. R. Scott Struthers Ph.D. (Age 62)Founder, President, CEO & Director Comp: $870.69kDr. Stephen F. Betz Ph.D. (Age 58)Founder & Chief Scientific Officer Comp: $618.58kMr. Marc J. C. Wilson (Age 45)Chief Financial Officer Comp: $585.54kMr. James Hassard (Age 58)Chief Commercial Officer Comp: $513.34kDr. Dana Pizzuti M.D. (Age 68)Chief Development Officer Comp: $493.62kMr. Jeff E. Knight (Age 53)Chief Operating Officer Comp: $237.64kMs. Garlan AdamsGeneral Counsel & Corporate SecretaryMs. Adriana Cabre M.B.A.Chief Human Resources OfficerDr. Alan S. Krasner M.D. (Age 61)Chief Medical Officer Comp: $571.97kMr. Kevin CappsHead of Intellectual PropertyMore ExecutivesKey CompetitorsBiohavenNYSE:BHVNUltragenyx PharmaceuticalNASDAQ:RAREPrestige Consumer HealthcareNYSE:PBHInsmedNASDAQ:INSMHUTCHMEDNASDAQ:HCMView All CompetitorsInsiders & InstitutionsJennison Associates LLCBought 270,171 shares on 5/2/2024Ownership: 3.579%BNP Paribas Financial MarketsSold 134,535 shares on 5/1/2024Ownership: 0.058%Mirae Asset Global Investments Co. Ltd.Sold 6,693 shares on 5/1/2024Ownership: 0.041%Principal Financial Group Inc.Sold 909 shares on 4/29/2024Ownership: 0.022%China Universal Asset Management Co. Ltd.Bought 5,643 shares on 4/29/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions CRNX Stock Analysis - Frequently Asked Questions Should I buy or sell Crinetics Pharmaceuticals stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CRNX shares. View CRNX analyst ratings or view top-rated stocks. What is Crinetics Pharmaceuticals' stock price target for 2024? 11 brokers have issued 1 year price objectives for Crinetics Pharmaceuticals' shares. Their CRNX share price targets range from $35.00 to $80.00. On average, they expect the company's stock price to reach $54.00 in the next year. This suggests a possible upside of 16.1% from the stock's current price. View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts. How have CRNX shares performed in 2024? Crinetics Pharmaceuticals' stock was trading at $35.58 on January 1st, 2024. Since then, CRNX stock has increased by 30.7% and is now trading at $46.50. View the best growth stocks for 2024 here. Are investors shorting Crinetics Pharmaceuticals? Crinetics Pharmaceuticals saw a increase in short interest in April. As of April 15th, there was short interest totaling 5,220,000 shares, an increase of 6.3% from the March 31st total of 4,910,000 shares. Based on an average trading volume of 802,900 shares, the days-to-cover ratio is presently 6.5 days. View Crinetics Pharmaceuticals' Short Interest. When is Crinetics Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CRNX earnings forecast. How can I listen to Crinetics Pharmaceuticals' earnings call? Crinetics Pharmaceuticals will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Crinetics Pharmaceuticals' earnings last quarter? Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.89) by $0.01. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 52.93% and a negative net margin of 4,223.27%. The firm's revenue for the quarter was down 100.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.84) EPS. What ETFs hold Crinetics Pharmaceuticals' stock? ETFs with the largest weight of Crinetics Pharmaceuticals (NASDAQ:CRNX) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), BNY Mellon Innovators ETF (BKIV) and First Trust BuyWrite Income ETF (FTHI). What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO? 6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend. What other stocks do shareholders of Crinetics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC). When did Crinetics Pharmaceuticals IPO? Crinetics Pharmaceuticals (CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO. Who are Crinetics Pharmaceuticals' major shareholders? Crinetics Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (3.58%), BNP Paribas Financial Markets (0.06%), Hennion & Walsh Asset Management Inc. (0.05%), Mirae Asset Global Investments Co. Ltd. (0.04%), HighMark Wealth Management LLC (0.02%) and Principal Financial Group Inc. (0.02%). Insiders that own company stock include Ajay Madan, Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers, Stephanie Okey and Stephen F Betz. View institutional ownership trends. How do I buy shares of Crinetics Pharmaceuticals? Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRNX) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsElon to Transform U.S. Economy? Porter & CompanyIncredible Opportunity to Retire FAST!Crypto 101 MediaGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
